SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Amendment No. 1
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 14, 2012
VANDA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)
(State or other jurisdiction of incorporation)
2200 Pennsylvania Avenue NW
Washington, DC 20037
(Address of principal executive offices and zip code)
Registrants telephone number, including area code: (202) 734-3400
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
(d) On June 18, 2012, Vanda Pharmaceuticals Inc. (the Company) filed a Current Report on Form 8-K (the Form 8-K) announcing that the Companys Board of Directors (the Board) had elected Michael Cola as a director of the Company and a member of the Audit Committee of the Board, effective as of June 14, 2012. The Form 8-K incorrectly stated that Mr. Colas initial term would expire at the Companys 2015 annual meeting of stockholders. Mr. Colas initial term will expire at the Companys 2013 annual meeting of stockholders. This Amendment No. 1 amends the Form 8-K solely for purposes of correcting this statement. The remainder of the Form 8-K shall not be effected by the filing of this Amendment No.1.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 25, 2012